Fitting mSMART Into Management of Waldenström Macroglobulinemia—Reply

In Reply The mSMART consensus statements take into account evidence-based approaches reflecting our preferred and tested management strategies in Waldenström macroglobulinemia (WM), outside clinical trials, and are published to facilitate delivery of high-quality care, particularly by clinicians who infrequently encounter this rare cancer. We recognize the paucity of high-level evidence in WM and have already highlighted in Table 3 of our article the key differences with the other existing guidelines that Castillo and colleagues from the Dana-Farber Cancer Institute point out.

from Cancer via ola Kala on Inoreader https://ift.tt/2EspnEp
via IFTTT